GlassScriptPhysician profile
Ashley T Evans
NPI 1326238981
$69,076.30
in general payments reported to CMS, 2019-2025
30 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $6,000 · 2021: $13K · 2022: $20K · 2023: $5,200 · 2024: $1,012 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,548 · Food and Beverage: $2,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,547.50 |
| Food and Beverage | $2,806.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $53,192.15 | 2019-2025 | |
| Janssen Biotech, INC. | $6,690.37 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $5,050.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,517.91 | 2019-2025 | Xifaxan |
| Celgene Corporation | $904.58 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $329.07 | 2023-2025 | Entyvio, Eohilia |
| Pfizer INC. | $171.03 | 2019-2025 | |
| Genzyme Corporation | $164.03 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $134.68 | 2023-2025 | Dupixent |
| Ucb, INC. | $128.53 | 2019 | |
| Madrigal Pharmaceuticals | $126.85 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $124.99 | 2019 | |
| Baxter Healthcare | $100.88 | 2024 | Tisseel |
| Stryker Corporation | $61.38 | 2024 | Neptune |
| Lilly USA, LLC | $58.31 | 2024-2025 | Omvoh |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $44.50 | 2024-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $41.61 | 2025 | Zenpep, Vowst |
| Ipsen Biopharmaceuticals, INC | $24.44 | 2025 | |
| Phathom Pharmaceuticals, INC. | $24.04 | 2025 | Voquezna |
| Mallinckrodt Hospital Products INC. | $21.10 | 2025 | Terlivaz |
| Tersera Therapeutics LLC | $20.41 | 2025 | Xermelo |
| Medtronic USA, INC. | $20.39 | 2019 | |
| Celltrion USA INC. | $20.15 | 2024 | Vegzelma |
| Allergan, INC. | $19.66 | 2019 | |
| Gilead Sciences, INC. | $16.13 | 2025 | |
| Fresenius Kabi USA, LLC | $15.44 | 2023 | Idacio |
| Ferring Pharmaceuticals INC. | $14.43 | 2019 | |
| Cook Medical LLC | $13.77 | 2023 | Instinct |
| Boston Scientific Corporation | $13.51 | 2021 | |
| Intercept Pharmaceuticals, INC. | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.